Among phlebotomy-dependent patients with polycythemia vera, the addition of rusfertide to standard-of-care treatment resulted ...
Protagonist Therapeutics notches a milestone in its pact with Takeda for rusfertide. New data show that many patients with a ...
Takeda and Protagonist Therapeutics have reported positive topline outcomes from their Phase III VERIFY trial of rusfertide ...
Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...
Rusfertide outperformed placebo in polycythemia vera, meeting all primary and secondary end points in the phase 3 VERIFY ...
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the Phase 3 V ...
Tuition, fees, textbooks, uniforms, equipment, and certification exams are covered for qualified students under a grant.
Phlebotomy Technicians are essential to proper healthcare worldwide as they are responsible for drawing blood needed for tests, donations, transfusions, and research. As the population ages and ...
NEW YORK--(BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health services, today announced the acquisition of PTI Health, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback